Tag: Eosinophilic asthma

Affecting approximately 5-10% of asthma patients, severe asthma can remain uncontrolled despite standard treatments. When asking what is the strongest medication for asthma, the answer is complex and involves advanced, highly targeted therapies beyond traditional inhalers.

As of late 2025, there is no generic for Fasenra injection, because it is a biologic medication, not a traditional chemical drug. Instead of generics, complex biologics like Fasenra (benralizumab) may one day have "biosimilars," but these are not yet approved.

While Fasenra (benralizumab) is an effective add-on maintenance treatment for severe eosinophilic asthma and EGPA, it is not without its challenges. A significant reported issue is its high cost, with some patients citing a major financial burden despite effective symptom control. Furthermore, like all medications, it carries a risk of side effects, ranging from common, mild reactions to rare, serious allergic responses.

According to the American Academy of Allergy, Asthma & Immunology, several biologics are effective for severe asthma when standard treatments fail. For patients and clinicians, understanding **what is comparable to Fasenra** is a critical step in tailoring treatment to a patient's specific inflammatory profile.

According to the American Academy of Allergy, Asthma & Immunology, biologics like benralizumab represent a significant shift in managing severe asthma. In addressing the question: **Is benralizumab an immunotherapy?** the answer is complex, as it is a specialized biologic that modulates the immune system but is distinct from classical allergen immunotherapy.

First approved by the FDA in 2017, benralizumab is a biologic medication known as a monoclonal antibody. This targeted treatment is specifically used for certain severe inflammatory conditions, primarily severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA), that are driven by high levels of eosinophils in the body.